Indivior PLC Ordinary Shares

Indivior Pharmaceuticals Inc. reported second-quarter 2026 adjusted earnings of $1.15 per share, up 125.5% year over year and beating the Zacks Consensus Estimate of 97 cents, while total revenues rose 13.6% to $343 million, also surpassing expectations. The company raised its full-year 2026 net revenue guidance to $1.295-$1.365 billion from $1.215-$1.285 billion, and lifted its total Sublocade net revenue forecast to $1.01-$1.05 billion from $950-$990 million, reflecting stronger-than-expected commercial performance. Adjusted EBITDA for the quarter surged 111% to $186 million, and the company repurchased about 4.7 million shares for $175 million at an average price of $37.52. Shares have declined 5.3% since the earnings report, underperforming the S&P 500, but the stock holds a Zacks Rank #2 (Buy) with upward estimate revisions.

Several major acquisition agreements were announced this week. DoubleVerify agreed to be acquired by Nielsen in an all-cash transaction valued at approximately $2.15 billion, with shareholders receiving $13.60 per share. Advanced Micro Devices signed a definitive agreement to acquire Taalas, a developer of specialized AI inference silicon. Visa agreed to acquire BioCatch, a provider of behavioral-first fraud intelligence, for $2.4 billion from funds advised by Permira. Prologis reached an agreement to buy SEGRO plc for about $18.8 billion after securing a board recommendation. Bending Spoons is acquiring Airtable in an all-cash transaction valuing the workflow software company at an enterprise value of $1.285 billion, implying an equity value of about $2.25 billion. Curium announced a deal to acquire all outstanding shares of Lantheus Holdings for up to $114.50 per share in cash, including contingent value rights. Atkore entered into a definitive agreement to be acquired by Prysmian in an all-cash transaction representing an enterprise value of approximately $3.8 billion. Supernus Pharmaceuticals and Indivior Pharmaceuticals agreed to merge in an all-stock merger of equals. Digital Brands Group shares surged after receiving a proposal from an existing shareholder to acquire all outstanding shares for $77.58 per share in cash. Gloo entered into a definitive agreement to acquire Cedarstone, a business services firm serving nonprofit organizations.

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form a diversified biopharmaceutical company focused on central nervous system disorders. The combined entity is expected to generate pro forma net revenue of $2.2 billion and will unite commercial portfolios spanning 11 medicines in neurology, addiction, and psychiatry. Supernus brings assets including ADHD drug Qelbree and Parkinson’s treatment Gocovri, while Indivior contributes opioid use disorder therapies such as Sublocade, which recorded $856 million in 2025 revenue. The merger is projected to deliver around $125 million in annual cost synergies and is anticipated to close in the fourth quarter of 2026, with Supernus CEO Jack Khattar leading the new company, which will trade on Nasdaq under the ticker SUPN.

Five biotech stocks profiled by RTTNews reached new 52-week highs last week, with gains ranging from 105% to 235% since their respective publication dates. Twist Bioscience soared 235% to a high of $104.23, driven by strong revenue and an upcoming quarterly report. Biodesix climbed 124% to $23.34 following better-than-expected results, raised guidance, and positive clinical validation data. Mirum Pharmaceuticals rose 133% to $124.44 on consistent revenue growth, the Bluejay Therapeutics acquisition, and positive trial results for Brelovitug and Volixibat. Candel Therapeutics advanced 108% to $9.99 after extended survival data for Aglatimagene and a commercialization agreement with EVERSANA. Indivior Pharmaceuticals gained 105% to $42.81, supported by solid earnings, upbeat guidance, and real-world evidence favoring Sublocade.

Indivior Pharmaceuticals is seeing its stock rise 15.6% year to date, outperforming an industry decline of 6.8%, as its once-monthly injectable opioid use disorder treatment Sublocade drives growth. Since its 2018 launch, more than 500,000 U.S. patients have received Sublocade, and management expects U.S. dispense-unit growth to accelerate to the mid-teens in 2026. The company has discontinued internal development of pipeline drugs INDV-6001 and INDV-2000 to focus on higher-value opportunities and is executing a cost-optimization program. Indivior currently holds a Zacks Rank #1 (Strong Buy), with 2026 and 2027 earnings per share estimates unchanged at $4.05 and $4.27, respectively.